THOUSAND OAK, California., September 16, 2020 / PRNewswire / – Amgen (NASDAQ: AMGN) will host two webcast calls for the investment community in conjunction with the European Society for Medical Oncology (ESMO) Virtual Congress 2020. Sunday, September 20, 2020 at 11:00 a.m. PDT, David M. Reese, MD, executive vice president of research and development at Amgen, along with members of the Amgen clinical development team and clinical researchers, will discuss the Phase 1 data presented on the company’s experimental KRASG12C sotorasib inhibitor (AMG 510). Sure Monday September 21, at 1:00 p.m. PDT, David M. Reese, MD, along with members of Amgen’s clinical development team, will discuss the Phase 1 data presented on the company’s extended experimental half-life for bispecific T cells (BiTE®) immuno-oncology therapy targeting prostate specific membrane antigen (PSMA).
Live audio of the investor call will be simultaneously broadcast over the Internet and will be made available to members of the news media, investors and the general public.
The webcast, as with other selected presentations regarding developments in Amgen’s business given at selected investor and medical conferences, can be viewed on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and links to webcasts can be found in the Amgen Investor Relations calendar of events. The webcast will be archived and available for replay for at least 90 days after the event.
Amgen is committed to unlocking the potential of biology for critically ill patients by discovering, developing, manufacturing and delivering innovative human therapies. This approach begins with the use of tools such as advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas where medical needs are not being met and uses its expertise to seek solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown into one of the world’s leading independent biotechnology companies, reaching millions of patients worldwide and developing a pipeline of disruptive drugs.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
CONTACT: Amgen, Thousand Oaks
Megan Fox, 805-447-1423 (media)
Trish rowland, 805-447-5631 (media)
Arvind Sood, 805-447-1060 (investors)